Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Pyrroles
  • Sirolimus

abstract

  • The combination of everolimus and sunitinib is associated with significant acute and chronic toxicities and is only tolerated at attenuated doses. Responses were observed in nonclear cell and clear cell RCC.

publication date

  • April 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3609026

Digital Object Identifier (DOI)

  • 10.1002/cncr.26429

PubMed ID

  • 21898375

Additional Document Info

start page

  • 1868

end page

  • 76

volume

  • 118

number

  • 7